Follow
Lutz Harnisch
Lutz Harnisch
Regeneron, Executive Director, Head Quantitative Pharmacology
Verified email at regeneron.com
Title
Cited by
Cited by
Year
Good practices in model‐informed drug discovery and development: practice, application, and documentation
EFPIA MID3 Workgroup, SF Marshall, R Burghaus, V Cosson, ...
CPT: pharmacometrics & systems pharmacology 5 (3), 93-122, 2016
2542016
Lack of efficacy of the selective iNOS inhibitor GW274150 in prophylaxis of migraine headache
HO H°ivik, BE Laurijssens, LO Harnisch, CK Twomey, RM Dixon, ...
Cephalalgia 30 (12), 1458-1467, 2010
902010
Drug and disease model resources: a consortium to create standards and tools to enhance model‐based drug development
L Harnisch, I Matthews, J Chard, MO Karlsson
CPT: Pharmacometrics & Systems Pharmacology 2 (3), 1-3, 2013
472013
Modeling and simulation as a tool to bridge efficacy and safety data in special populations
L Harnisch, T Shepard, G Pons, O Della Pasqua
CPT: pharmacometrics & systems pharmacology 2 (2), 1-4, 2013
442013
Pharmacometrics Markup Language (PharmML): opening new perspectives for model exchange in drug development
MJ Swat, S Moodie, SM Wimalaratne, NR Kristensen, M Lavielle, A Mari, ...
CPT: pharmacometrics & systems pharmacology 4 (6), 316-319, 2015
412015
Population kinetics of gentamicin in neonates
W Weber, G Kewitz, KL Rost, M Looby, M Nitz, L Harnisch
European Journal of Clinical Pharmacology 44, S23-S25, 1993
401993
Elucidation of factor VIII activity pharmacokinetics: a pooled population analysis in patients with hemophilia A treated with moroctocog alfa
JA Abrantes, EI Nielsen, J Korth‐Bradley, L Harnisch, S J÷nsson
Clinical Pharmacology & Therapeutics 102 (6), 977-988, 2017
282017
Advancing clinical trial design in pulmonary hypertension
AP Grieve, SC Chow, J Curram, S Dawe, LO Harnisch, NR Henig, ...
Pulmonary circulation 3 (1), 217-225, 2013
252013
Application of quantitative pharmacology approaches in bridging pharmacokinetics and pharmacodynamics of domagrozumab from adult healthy subjects to pediatric patients withá…
I Bhattacharya, Z Manukyan, P Chan, A Heatherington, L Harnisch
The Journal of Clinical Pharmacology 58 (3), 314-326, 2018
212018
Efficacy and tolerability of the iNOS inhibitor GW274150 administered up to 120 mg daily for 12 weeks in the prophylactic treatment of migraine
K Hoye, BE Laurijssens, LO Harnisch, CK Twomey, RM Dixon, A Kirkham
Cephalalgia 29 (1), 132, 2009
212009
Efficacy of 1, 5, and 20 mg oral sildenafil in the treatment of adults with pulmonary arterial hypertension: a randomized, double-blind study with open-label extension
CD Vizza, BKS Sastry, Z Safdar, L Harnisch, X Gao, M Zhang, M Lamba, ...
BMC pulmonary medicine 17, 1-12, 2017
192017
Towards regulatory endorsement of drug development tools to promote the application of model-informed drug development in Duchenne muscular dystrophy
DJ Conrado, J Larkindale, A Berg, M Hill, J Burton, KR Abrams, ...
Journal of pharmacokinetics and pharmacodynamics 46, 441-455, 2019
172019
Lessons learned from a phase III population pharmacokinetic study of cariporide in coronary artery bypass graft surgery
W Weber, L Harnisch, A Jessel
Clinical Pharmacology & Therapeutics 71 (6), 457-467, 2002
172002
Use of a population pharmacokinetic model to predict clinical outcome of leflunomide, a new DMARD in the treatment of rheumatoid arthritis.
W Weber, L Harnisch
ARTHRITIS AND RHEUMATISM 40 (9), 731-731, 1997
141997
Model description language (MDL): a standard for modeling and simulation
MK Smith, SL Moodie, R Bizzotto, E Blaudez, E Borella, L Carrara, ...
CPT: pharmacometrics & systems pharmacology 6 (10), 647, 2017
122017
Making every subject count: a case study of drug development path for medication in a pediatric rare disease
I Bhattacharya, Z Manukyan, P Chan, L Harnisch, A Heatherington
Clinical Pharmacology & Therapeutics 100 (4), 330-332, 2016
112016
Modeling of survival and frequency of cardiovascular-related hospitalization in patients with transthyretin amyloid cardiomyopathy treated with tafamidis
C Vong, M Boucher, S Riley, LO Harnisch
American Journal of Cardiovascular Drugs 21, 535-543, 2021
102021
The population approach: measuring and managing variability in response, concentration and dose
W Weber, L Harnisch
COST B1 medicine: European cooperation in the field of scientific andá…, 1997
81997
The effect of activated charcoal and cholestyramine on the pharmacokinetics of leflunomide
HJ Roethig, J Collins, L Harnisch, C Rokitta, W Weber
Clinical Pharmacology & Therapeutics 59 (2), 204-204, 1996
81996
Thoughtflow: standards and tools for provenance capture and workflow definition to support model‐informed drug discovery and development
JJ Wilkins, PLS Chan, J Chard, G Smith, MK Smith, M Beer, A Dunn, ...
CPT: Pharmacometrics & Systems Pharmacology 6 (5), 285-292, 2017
62017
The system can't perform the operation now. Try again later.
Articles 1–20